Brean Murray Carret & Co. Downgrades Pharmasset (VRUS) to Hold; Near-Perfect Fit

Brean Murray Carret & Co. downgraded Pharmasset (NASDAQ: VRUS) from Buy to Hold.

Brean analyst says, "Gilead's decision to acquire Pharmasset for its pipeline of nucleotide analogs in development for Hep C carries risk, but can potentially be a big win for the company that has made a name by dominating market share in HIV and Hep B. We believe VRUS is a near-perfect fit for the company that revolutionized the use of nuc combo therapy in viral infections. Given the premium, we believe it is unlikely that another player will come to the table with a higher offer."

For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.

Shares of Pharmasset closed at $134.14 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
• Citizens Downgrades SoundThinking (SSTI) to Market Perform
• Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward